Protective properties of a human IgG preparation rich in antibodies to a wide spectrum of lipopolysaccharides

Naturally occurring human IgG, rich in antibodies to different lipopolysaccharides was investigated for possible protective effects against lethal endotoxin shock and lethal gram‐negative infection in mice. The IgG preparation was obtained from pooled serum of selected blood donors with high concentrations of antibodies to 11 different LPS as measured by ELISA. The human IgG (5 mg/mouse) protected C3H/TifF mice against an otherwise lethal infection with Salmonella typhimurium. The human IgG also inhibited the lethality induced by purified LPS in D‐galactosamine sensitized C57B1/6 mice. The protection was dependent on the IgG dose given. However, protection was not obtained against all the LPS preparations tested. Absorption of the IgG with different LPS, showed the protection to be caused by serotype‐specific anti‐LPS antibodies. Protection against a given LPS was not related directly to the corresponding anti‐LPS titer as measured by ELISA and passive hemolysis. The interpretation of these results is discussed.

[1]  K. Bendtzen,et al.  Immunochemical and Biological Reactivity of Human Anti‐Lipopolysaccharide IgG Obtained by Screening of Blood Donors , 1989, Scandinavian journal of immunology.

[2]  J. Schellekens,et al.  Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. , 1988, The Journal of infectious diseases.

[3]  W. R. Mccabe,et al.  Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. , 1988, The Journal of infectious diseases.

[4]  E. Ziegler.  Protective antibody to endotoxin core: the emperor's new clothes? , 1988, The Journal of infectious diseases.

[5]  C. Galanos,et al.  Induction of Lethality and Tolerance by Endotoxin Are Mediated by Macrophages through Tumor Necrosis Factor , 1988 .

[6]  S. E. Greisman,et al.  Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality. , 1988, The Journal of infectious diseases.

[7]  A. Fomsgaard,et al.  Anti-lipopolysaccharide antibodies measured by enzyme-immunoassay in Danish blood donors. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

[8]  A. Fomsgaard,et al.  ENDOTOXINAEMIA IN TOXIC SHOCK SYNDROME TREATED WITH ANTI-ENDOTOXIN ANTIBODIES , 1987, The Lancet.

[9]  M. Glauser,et al.  Controversies in the use of passive immunotherapy for bacterial infections in the critically ill patient. , 1987, Reviews of infectious diseases.

[10]  A. Fomsgaard,et al.  ELISA for human IgG and IgM anti-lipopolysaccharide antibodies with indirect standardization. , 1987, Journal of immunoassay.

[11]  R. Ulevitch,et al.  Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum , 1986, The Journal of experimental medicine.

[12]  J. McCutchan,et al.  PREVENTION OF GRAM-NEGATIVE SHOCK AND DEATH IN SURGICAL PATIENTS BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPID , 1985, The Lancet.

[13]  S. Gaffin.  Gram-negative bacteraemia: new therapeutic possibilities with anti-endotoxin antibodies. , 1985, Haematology and blood transfusion.

[14]  C. Galanos,et al.  Immunogenic properties of lipid A. , 1984, Reviews of infectious diseases.

[15]  L. Baek.  New, sensitive rocket immunoelectrophoretic assay for measurement of the reaction between endotoxin and Limulus amoebocyte lysate , 1983, Journal of clinical microbiology.

[16]  W. R. Mccabe,et al.  Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin. , 1983, The Journal of infectious diseases.

[17]  J. McCutchan,et al.  TREATMENT OF GRAM-NEGATIVE BACTEREMIA AND SHOCK WITH HUMAN ANTISERUM TO A MUTANT ESCHERICHIA COLI , 1983 .

[18]  J. Fierer,et al.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1982, The New England journal of medicine.

[19]  J. Pennington,et al.  Type-specific vs. cross-protective vaccination for gram-negative bacterial pneumonia. , 1981, The Journal of infectious diseases.

[20]  L. Leive,et al.  Heterogeneity of antigenic-side-chain length in lipopolysaccharide from Escherichia coli 0111 and Salmonella typhimurium LT2. , 1980, European journal of biochemistry.

[21]  W. Reutter,et al.  Galactosamine-induced sensitization to the lethal effects of endotoxin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Ward,et al.  Isolation from human serum of an inactivator of bacterial lipopolysaccharide. , 1977, The American journal of pathology.

[23]  E. Rietschel,et al.  Lipid A antiserum-mediated protection against lipopolysaccharide- and lipid A-induced fever and skin necrosis , 1977, Infection and immunity.

[24]  W. R. Mccabe,et al.  Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. , 1976, The Journal of infectious diseases.

[25]  C. Galanos,et al.  Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms. , 1975, European journal of biochemistry.

[26]  A. Braude,et al.  Treatment and prevention of intravascular coagulation with antiserum to endotoxin. , 1973, The Journal of infectious diseases.

[27]  A. Braude,et al.  Passive immunization against the local Shwartzman reaction. , 1972, Journal of immunology.

[28]  C. Galanos,et al.  Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. , 1971, European journal of biochemistry.

[29]  C. Galanos,et al.  A new method for the extraction of R lipopolysaccharides. , 1969, European journal of biochemistry.

[30]  I. Čižnár,et al.  Lipopolysaccharides of Gram-Negative Bacteria , 2019, Handbook of Biochemistry and Molecular Biology.

[31]  O. Westphal.  Bacterial lipopolysaccharides : extraction with phenol-water and further applications of the procedure , 1965 .